GeneDx reports quarterly losses of 33 cents per share which beat the analyst consensus estimate of losses of 67 cents by 50.75%. The company reported quarterly sales of $62.422 million which beat the analyst consensus estimate of $49.463 million by 26.2%.
In this article, we will be taking a look at the 20 most valuable digital health companies in the US. If you are not interested in reading about the global health market, head straight to the 5 Most Valuable Digital Health Companies In The US. As of the latest data, several digital health companies stand […]
Reported fourth quarter 2023 revenue from continuing operations1 of $58.1M with more than 68% year-over-year growth of exome and genome test revenue Expanded fourth quarter 2023 adjusted gross.